Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUCYNTA ER vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of moderate to severe chronic pain in adults requiring around-the-clock treatment,Conversion from other opioids (off-label)
Mild to moderate pain,Fever
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation (UGT1A9, UGT2B7) and to a lesser extent via CYP2C9 and CYP2C19; tapentadol-O-glucuronide is the major inactive metabolite.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 80% bound; primarily to albumin and alpha-1 acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
540 L (equivalent to ~7.7 L/kg for 70 kg); indicates extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral (ER): 32% (due to first-pass metabolism); absolute bioavailability of immediate-release tapentadol is 32% as well.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl 30-90 m L/min: no adjustment; Cr Cl <30 m L/min: not recommended; end-stage renal disease: contraindicated.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for pediatric use; safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50 mg every 12 hours; titrate cautiously; monitor for respiratory depression and cognitive impairment.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion causing fatal overdose in children; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression, especially in elderly or debilitated patients; risk of hypotension and syncope; risk of serotonin syndrome when co-administered with serotonergic drugs; risk of adrenal insufficiency; risk of severe hypotension including orthostatic hypotension; risk of seizures in patients with seizure disorders; risk of withdrawal if abruptly discontinued; not for use in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected gastrointestinal obstruction including paralytic ileus.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to tapentadol or any components of the product; concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice may increase tapentadol levels. Avoid alcohol as it increases CNS depression and risk of respiratory depression. No specific food restrictions beyond moderation.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. There is insufficient data on NUCYNTA ER (tapentadol) specifically for teratogenic risk; however, based on other opioids and animal studies, there may be an increased risk of neural tube defects and other malformations with first-trimester exposure. Second and third-trimester exposure may lead to fetal dependence and withdrawal. Use only if benefit outweighs risk.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Tapentadol is excreted in human milk. The milk-to-plasma concentration ratio (M/P) is approximately 1.3. The relative infant dose is estimated to be 0.1-0.4% of the maternal weight-adjusted dose. Caution is advised; monitor infant for signs of opioid toxicity, such as sedation or respiratory depression. Consider alternate analgesia if infant is at risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy can alter pharmacokinetics of tapentadol due to increased blood volume, renal blood flow, and metabolic enzyme induction. However, no specific dose adjustment guidelines are established. Use the lowest effective dose for the shortest duration, monitor maternal response, and consider dose adjustments based on pain relief and adverse effects. Taper gradually to avoid withdrawal in both mother and neonate.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
NUCYNTA ER (tapentadol) is a Schedule II controlled substance with mu-opioid agonist and norepinephrine reuptake inhibitor activity. Extended-release formulation is not interchangeable with immediate-release on a mg-per-mg basis. Do not crush, chew, or dissolve tablets. Use with caution in patients with severe renal or hepatic impairment; contraindicated in severe hepatic impairment. Monitor for respiratory depression, especially at initiation and dose escalation. Avoid use with MAOIs or within 14 days; serotonergic drugs increase risk of serotonin syndrome.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Swallow tablets whole; do not crush, chew, or dissolve.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives).,May cause drowsiness or dizziness; avoid driving until response is known.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely out of reach of children; dispose of unused medication via take-back programs.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUCYNTA ER vs ACEPHEN, answered by our medical review team.
NUCYNTA ER is a Opioid Analgesic that works by Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUCYNTA ER and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUCYNTA ER is: 100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUCYNTA ER and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUCYNTA ER is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. There is insufficient data on NUCYNTA ER (tapentadol) specifically for teratogenic risk. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.